4 Healthcare Stock Stories For a Midweek Investment Checkup
Sanofi-Aventis (NYSE:SNY): Closing price $52.28
Sanofi shares were upgraded by analysts at Berenberg Bank from Hold to Buy in a research report released to clients and investors on Wednesday, according to StockRatingsNetwork.com. The stock opened at $51.81 and closed at $52.28, up 0.91 percent on the day. The stock’s 50-day moving average presently stands at $51.91. The firm has a market cap of $137.4 billion and a price-to-earnings ratio of 30.82.
Novartis (NYSE:NVS): Closing price $73.73
Novartis said Wednesday that results of its global Phase III study indicate that Afinitor (everolimus) did not extend overall survival versus placebo in patients suffering with locally advanced or metastatic hepatocellular carcinoma after progression on or intolerance to sorafenib. Hepatocellular carcinoma, which is an aggressive and debilitating cancer, is the most common type of liver cancer. Novartis will thus not proceed with regulatory filings of Afinitor in this indication.
Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA): Closing price $38.85
Teva’s American subsidiary Teva Women’s Health, announced that the emergency contraceptive Plan B One-Step (levonorgestrel) tablet 1.5 mg is now widely available in the aisles of major retailers spanning the United States without age and point-of-sale restrictions. Plan B One-Step is the initial emergency contraceptive to be available for over-the-counter sales to all consumers. Even though there are many highly effective birth control options available, none are 100 percent effective at preventing pregnancy, and inconsistent or incorrect can raise the failure rate by a factor of two of several birth control options.
Cleveland BioLabs, Inc. (NASDAQ:CBLI): Closing price $1.70
Cleveland BioLabs and Incuron, LLC, a joint venture between the former and Bioprocess Capital Ventures, reported Wednesday that a multi-center, Phase 1, single agent, dose escalation trial evaluating intravenous administration of CBL0137 in patients suffering with metastatic or unresectable advanced solid cancers and lymphomas is open for enrollment, and that treatment of the first patient has begun. The primary goal of the study is to determine the maximally tolerated dose and recommend a Phase 2 dose for CBL0137 in these patients. Secondary objectives include outlining the dose limiting toxicity, adverse event and pharmacokinetic profile of CBL0137, together with documenting any objective responses.